Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2009 Sep 1;8(9):2509–2516. doi: 10.1158/1535-7163.MCT-09-0386

Figure 2.

Figure 2

Triptolide decreases XIAP, Mcl-1, and Bcr-Abl levels in CML cells. (A) K562 cells were treated with 100 nM of triptolide. XIAP and Mcl-1 mRNA levels were determined at various time points by Real-time RT-PCR. (B) K562 cells were treated with various concentrations of triptolide for 48 hours or with 100 nM of triptolide for various times. (C) KBM5 and KBM5STI571 cells were treated with triptolide for 24 hours and with imatinib for 24 to 72 hours and (D) cells from patients with CML were treated with triptolide for 24 hours. XIAP, Mcl-1, and Bcr-Abl protein levels were determined by western blot analysis and cell death was determined by annexin V staining.